ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1485 • ACR Convergence 2025

    Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index

    guru Vijay Chagalakondu and Vijaya prasanna Parimi, ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune condition presenting with unpredictable varying levels of severity. Thus, constant monitoring of disease activity is…
  • Abstract Number: 1469 • ACR Convergence 2025

    Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus

    Adriana Vázquez-Hernández1, Emilio Godinez-Lazarini2, Erik Cimé-Aké2 and Hilda Fragoso-Loyo3, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Distrito Federal, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 3Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico

    Background/Purpose: In systemic lupus erythematosus (SLE), differences have been observed between patients of different ages at onset. This study evaluates remission, low disease activity, and…
  • Abstract Number: 1277 • ACR Convergence 2025

    Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease

    Eileen Rife1, Daniel Reiff2, John Bridges3, Emily Smitherman1, randy Cron1, Matthew Stoll1, Melissa Mannion1, Peter Weiser4 and Livie Timmerman5, 1University of Alabama at Birmingham, birmingham, AL, 2Boys Town Hospital, Omaha, 3University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, 4University of Alabama at Birmingham, Birmingham, 5University of Alabama at Birmingham, Gardendale, AL

    Background/Purpose: Current practice guidelines recommend either rituximab (RTX) or cyclophosphamide (CYC) for treatment of organ-threatening manifestations of systemic vasculitis or connective tissue disease (e.g., diffuse…
  • Abstract Number: 1082 • ACR Convergence 2025

    Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients

    Rashi Vora1, Samiha Karim2, Dulaney Wilson3, Jasvinder Singh4, Gary Gilkeson1, Jim Oates1 and Diane Kamen5, 1Medical University of South Carolina, Charleston, SC, 2Emory University, Atlanta, GA, 3Medical University of South Carolina, Charleston, 4Baylor College of Medicine, Houston, TX, 5Medical University of South Carolina, Johns Island, SC

    Background/Purpose: Minority patients with systemic lupus erythematosus (SLE) experience a higher disease burden and encounter more barriers to care than White patients, resulting in worse…
  • Abstract Number: 0946 • ACR Convergence 2025

    A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice

    Juan Liang1 and Ting Wang2, 1Gempharmatech, Nanjing, Jiangsu, China, 2GemPharmatech, Nanjing, China (People's Republic)

    Background/Purpose: CD20, a well characterized B-cell surface marker involved in B-cell activation and differentiation, plays a critical role in the pathogenesis of B-cell mediated diseases…
  • Abstract Number: 0908 • ACR Convergence 2025

    E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease

    Hrishikesh Mehta1, Vijayashree Mysore1, Chih-Hsing Chou1, Lizhi Cao1, Rui Liu2, Tianrui Fan2, Jijun Yuan2, James Broderick1 and Li Peng1, 1Palleon Pharmaceuticals, Waltham, MA, 2Shanghai Henlius Biotech, Shanghai, China (People's Republic)

    Background/Purpose: Abnormal cell surface glycosylation has been observed in various autoimmune diseases, including systemic lupus erythematosus (SLE) and membranous nephropathy. Among these glycan modifications, sialoglycans…
  • Abstract Number: 0653 • ACR Convergence 2025

    In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at their Clinical Dose Regimens

    May-Linda Lepage1, Patrick Nolain1, Céline Cottereaux1, Emilie Lagoutte1, Justine Dao1, Adrien Cosson1, Laetitia Furio1, Willem Hettema2, Chantal Tasset3, Roland Blanqué1, Isabelle Parent1 and René Galien1, 1Galapagos SASU, Paris, France, 2Galapagos B.V., Leiden, Netherlands, 3Galapagos NV, Mechelen, Belgium

    Background/Purpose: Tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member, is attracting a lot of interest as a new target to treat patients with…
  • Abstract Number: 0632 • ACR Convergence 2025

    Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study

    Rusudan Tskitishvili1, Abdallah Hussein2, Roman Karagulyan2, Shatha Shahwan3 and Priju Varghese2, 1Virtua Health, Camden, NJ, 2Virtua Health, Camden, 3Jordan University of Science and Technology, Jordan

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a heightened risk of cardiovascular and renal complications, particularly in patients with comorbid diabetes mellitus. While both…
  • Abstract Number: 0614 • ACR Convergence 2025

    Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound

    Ileana C. Reynosa-Silva1, Oscar Azael Garza-Flores2, Fernanda M. Garcia-Garcia3, Aleydis Gonzalez-Melendez1, Iris J. Colunga-Pedraza3, Dionicio A. Galarza-Delgado3, Jose R Azpiri-Lopez4, Rosa Arvizu-Rivera5, Jesus Alberto Cardenas-de la Garza6 and Diego Azamat Salcedo Almanza7, 1Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 4Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 5Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, 6Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, 7Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with an elevated risk of cardiovascular (CV) disease, largely due to chronic inflammation and…
  • Abstract Number: 0598 • ACR Convergence 2025

    Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases

    Jaspreet Bhatti1, Kyu-In Lee2, Nirali Sanghavi3, Stephen Zak4, Julia Ash5, James Miceli6, Kirk Sperber4, Stephen Pan7 and Amy Wasserman8, 1Westchester Medical Center, Hopewell Junction, NY, 2Westchester Medical Center, Fort Lee, NJ, 3Westchester Medical Center, White Plains, NY, 4New York Medical College, Valhalla, 5Westchester Medical center, Dobbs Ferry, NY, 6Westchester Medical Center, Hawthorne, NY, 7Westchester Medical Center, Valhalla, 8New York Medical College at Westchester Medical Center, Armonk, NY

    Background/Purpose: HCQ induced cardiomyopathy leading to heart failure is a rare but serious potential treatment complication. Currently there are no screening guidelines for detecting HCQ…
  • Abstract Number: 0804 • ACR Convergence 2025

    Comparative Risk of All-Cause Mortality with Belimumab versus Oral Immunosuppressant Use in Patients with Non-Renal Systemic Lupus Erythematosus

    Grace Haeun Lee1, Sara Barmettler2, Lingxiao Zhang3 and April Jorge2, 1Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Boston

    Background/Purpose: Belimumab is a monoclonal antibody targeting B-lymphocyte stimulator (BLyS) used in the treatment of active systemic lupus erythematosus (SLE). Our objective was to investigate…
  • Abstract Number: 0245 • ACR Convergence 2025

    Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study

    cristiana Sieiro1, Sarah Dyball2, Ellen Bruce3, Ben Parker4 and Ian Bruce5, 1Univrsity of Manchester, Manchester, United Kingdom, 2University of Manchester, Manchester, United Kingdom, 3Manchester University NHS FT, The Kellgren Centre of Rheumatology, Manchester, United Kingdom, Manchester, 4NIHR Manchester CRF, Manchester Royal Infirmary, Manchester, United Kingdom, 5Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom

    Background/Purpose: Connective tissue diseases (CTDs), including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjögren’s disease (SjD), are associated with an increased risk of cardiovascular…
  • Abstract Number: 0046 • ACR Convergence 2025

    Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease

    Thomas Riley1, Dana DiRenzo1, Ellen Romich2, Michael Levin3, Scott Damrauer3, Michael George1, Montserrat Anguera1, Joshua Baker1 and Nikhil Jiwrajka1, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Media, PA, 3University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA

    Background/Purpose: The mechanisms underlying female sex bias in autoimmune diseases remain unclear. Recent work has suggested that impaired maintenance of X-chromosome inactivation (XCI) in female…
  • Abstract Number: 2630 • ACR Convergence 2025

    The Absence of DORIS Remission Is Associated with Greater Risk of Preterm Birth and Preeclampsia in SLE Pregnancies

    Camila Hernández-Blanco1, Philip Carlucci2, Peter Izmirly3, Jessica Dai4, Mala Masson5, Michael Belmont1, Amit Saxena6, Jane Salmon7, Justin Brandt1 and Jill Buyon8, 1NYU Langone Health, New York, NY, 2New York University School of Medicine, New York, NY, 3New York University Grossman School of Medicine, New York, NY, 4New York University Grossman School of Medicine, Tenafly, NJ, 5NYU Langone Medical Center- Division of Rheumatology, New York, NY, 6Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 7Hospital for Special Surgery, New York, NY, 8NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) primarily affects females of childbearing age and increases the risk of adverse pregnancy outcomes (APOs), particularly in non-White individuals and…
  • Abstract Number: 2481 • ACR Convergence 2025

    Prevalence and Trends of Suicidal Ideation Among Hospitalized Adults with Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis (2016–2020)

    Fatima Khdeir and Aysheh Khdeir, ECU Health Medical Center, Greenville, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with psychiatric comorbidities, including depression and suicidal ideation. However, national trends over time have…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology